Drug Target Review
NOVEMBER 17, 2023
About the authors Aleta Pupovac Publications Officer, Cartherics Aleta is a cell biologist and immunologist who is passionate about translational science. In 2019, she joined Cartherics focusing on the science underpinning induced pluripotential stem cell differentiation to natural killer cells, and how to manufacture them.
Drug Target Review
NOVEMBER 24, 2023
Achieving a mouse brain map has been made possible by advances in computing and data processing, as well as previous work by Lichtman and other researchers like Professor Florian Engert in molecular and cell biology, studying the brains of fruit flies and zebrafish. 2015 February 5 [2023 October 17]; 9(19)1-3. What it is for?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
APRIL 9, 2024
Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects. In 2005, he joined CNIO to lead the Genomic Instability Group where he has been ever since.
Codon
APRIL 9, 2024
The existing literature written in English on this story tends to attribute Tu Youyou’s achievements to a solo discovery, an understandable consequence of Tu receiving the Nobel Prize in Physiology or Medicine in 2015. Miller and Su published an article on Tu’s story in Cell in 2011. Nobody had an answer.
Dark Matter Blog
APRIL 4, 2023
Prior to 2015, I had a casual relationship, at best, with targeting RNA. Targeting RNA is a Whole New World Then in 2015, I became smitten and eloped with RNA, setting out to build a company devoted to bringing to bear industrial drug discovery concepts and methods on a new problem of drugging RNA with small molecules.
DrugBank
JUNE 27, 2023
whitehouse.gov [link] (2015). Nature 526 , 68–74 (2015). Network expansion of genetic associations defines a pleiotropy map of human cell biology. Precision Medicine from a Public Health Perspective. Public Health 39 , 153–168 (2018). Obama White House Archive. Jaccard, E., Waeber, G. &
The Pharma Data
OCTOBER 22, 2020
About the Innate-AstraZeneca monalizumab agreement : On April 24, 2015, the Company signed a codevelopment and commercialization agreement with AstraZeneca to accelerate and broaden the development of monalizumab. Additional details on the INTERLINK-1 clinical trial can be found here.
Expert insights. Personalized for you.
118 
Let's personalize your content